Weight Loss GLP-1 Peptides Purity 99% CAS 2381089-83-2 Weight Management Obesity Treatment Ozempic (LY3437943) 10mg Tirzepatide Semaglutide Retatrutide

Lose 37 pounds in 6 months! Retatrutide opens the era of "tri-receptor agonists" for weight loss? NEJM publishes the latest research
 

Introduction: Recently, the latest phase 2 study data of the "tri-receptor agonist" Retatrutide for obesity treatment was published in the New England Journal of Medicine (NEJM, IF: 158.5). The study showed that: taking the drug once a week, at 24 weeks, the average weight loss of overweight/obese non-diabetic subjects in the Retatrutide 12mg group reached 18.7 kg (17.5%); in the secondary endpoint, the average weight loss of the Retatrutide 12mg group at the end of 48 weeks of treatment reached 26.2 kg (24.2%).

Retatrutide: Opening the era of "triple receptor agonist" for weight loss?
Retatrutide is a triple agonist peptide for glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide has a half-life of about 6 days and is administered once a week.
Compared with endogenous receptor ligands, Retatrutide has weaker effects on human GCG receptors and GLP-1 receptors (0.3 and 0.4 times, respectively), but stronger effects on human GIP receptors (8.9 times).
In 6 months, the average weight loss was 18.7 kg!
This Phase 2 study is a 48-week randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, tolerability and safety of Retatrutide at different doses and dose escalation regimens in overweight/obese non-type 2 diabetic subjects with weight-related comorbidities.

The study was conducted in the United States and included a total of 338 subjects. The subjects were randomly assigned in a ratio of 2:1:1:1:1:2:2 to receive Retatrutide 1 mg, 4 mg (initial dose of 2 mg), 4 mg (initial dose of 4 mg), 8 mg (initial dose of 2 mg), 8 mg (initial dose of 4 mg), 12 mg (initial dose of 2 mg) or placebo once a week by subcutaneous injection for 48 weeks. The primary endpoint was the percentage change in weight compared with baseline at week 24; secondary endpoints included the percentage of weight change from baseline to week 48 (weight loss ≥5%, ≥10% or ≥15%) and drug safety.
The results showed:
At 24 weeks, the average weight loss in the Retatrutide 12mg group was 18.7 kg (17.5%), the average weight loss in the 1mg group was 7.2%, the average weight loss in the 4mg group was 12.9%, and the average weight loss in the 8mg group was 17.3%. In contrast, the average weight loss in the placebo group was only 1.6%.
At 48 weeks, the average weight loss in the Retatrutide 12mg group was 26.2 kg (24.2%), the average weight loss in the 1mg group was 8.7%, the average weight loss in the 4mg group was 17.1%, and the average weight loss in the 8mg group was 22.8%. In contrast, the average weight loss in the placebo group was only 2.1%.